Hospital
Montgomery Regional Hospital INC
Montgomery Regional Hospital INC was paid $17.14M by Medicaid between Jan 2018 and Dec 2024, across 200 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoMONTGOMERY REGIONAL HOSPITAL INC
BLACKSBURG, VA 24060
BLACKSBURG, VA 24060
33aNPI1275570376assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.14M
24GClaims464,301
24DCodes billed200
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#38 of 80
Median peer was paid$14.69M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,547 | $1.22M | |
| 2019 | 73,166 | $1.85M | |
| 2020 | 54,883 | $1.86M | |
| 2021 | 65,229 | $2.11M | |
| 2022 | 76,567 | $2.94M | |
| 2023 | 82,516 | $3.77M | |
| 2024incomplete | 63,393 | $3.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 26,530 | 22,873 | $4.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 21,655 | 17,920 | $3.40M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 6,770 | 6,179 | $1.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 5,651 | 4,795 | $879K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 4,476 | 3,941 | $785K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.3% | 3,271 | 2,855 | $746K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 3,519 | 3,029 | $576K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 1,234 | 1,078 | $501K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.5% | 223 | 208 | $421K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 1,429 | 1,295 | $412K |
| G0378 | Hospital observation service, per hour | 2.4% | 5,042 | 2,622 | $408K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 1,940 | 1,781 | $331K |
188 more codes
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.7% | 278 | $294K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 4,791 | $182K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 785 | $178K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 925 | $170K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 283 | $135K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,418 | $127K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,129 | $126K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,775 | $113K |
| 80053 | Comprehensive metabolic panel | <1% | 31,755 | $110K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 733 | $99K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,751 | $95K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 336 | $63K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,197 | $61K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,439 | $59K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,647 | $59K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,612 | $59K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,549 | $59K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,807 | $59K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 603 | $59K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,775 | $55K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,632 | $50K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,069 | $46K |
| 85027 | <1% | 37,963 | $44K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 77 | $41K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 196 | $41K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,037 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,617 | $34K |
| 93971 | <1% | 374 | $29K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 168 | $28K |
| 87400 | <1% | 8,362 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 323 | $26K |
| 74018 | <1% | 1,307 | $26K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,214 | $23K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,514 | $22K |
| 42830 | <1% | 12 | $22K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 28 | $20K |
| 12001 | <1% | 108 | $20K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,469 | $19K |
| 93246 | <1% | 331 | $18K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 479 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,158 | $17K |
| 87040 | <1% | 3,632 | $17K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,106 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,742 | $16K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 222 | $16K |
| 76641 | <1% | 129 | $14K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,954 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,284 | $13K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 76 | $13K |
| 81025 | <1% | 5,328 | $12K | |
| 72110 | <1% | 1,316 | $12K | |
| 76536 | <1% | 111 | $11K | |
| 97163 | <1% | 163 | $11K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 498 | $11K |
| 90715 | <1% | 542 | $9K | |
| 87420 | <1% | 1,766 | $9K | |
| 73030 | <1% | 822 | $9K | |
| 10060 | <1% | 64 | $8K | |
| 93017 | <1% | 82 | $8K | |
| 73564 | <1% | 1,140 | $8K | |
| 84484 | <1% | 7,669 | $8K | |
| 73610 | <1% | 1,115 | $8K | |
| 73630 | <1% | 1,038 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 876 | $7K |
| 76857 | <1% | 241 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,428 | $6K |
| 85610 | <1% | 5,296 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,731 | $5K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,644 | $5K |
| 85379 | <1% | 1,431 | $5K | |
| 83735 | <1% | 6,416 | $5K | |
| 81001 | <1% | 12,138 | $4K | |
| 73130 | <1% | 600 | $4K | |
| 80061 | Lipid panel | <1% | 1,122 | $4K |
| 83690 | <1% | 8,271 | $4K | |
| 83605 | <1% | 3,887 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,772 | $4K |
| 83880 | <1% | 972 | $4K | |
| 80143 | <1% | 1,122 | $4K | |
| 84703 | <1% | 6,747 | $4K | |
| 76000 | <1% | 140 | $4K | |
| 12011 | <1% | 12 | $3K | |
| 96376 | <1% | 1,117 | $3K | |
| 86140 | <1% | 947 | $3K | |
| 87070 | <1% | 4,398 | $3K | |
| 73110 | <1% | 534 | $3K | |
| 87186 | <1% | 1,918 | $3K | |
| 70491 | <1% | 12 | $2K | |
| 82947 | <1% | 2,857 | $2K | |
| 84439 | <1% | 296 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 40 | $2K |
| 80179 | <1% | 1,069 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,985 | $2K |
| 80047 | <1% | 899 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 457 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 781 | $2K |
| 87077 | <1% | 1,600 | $2K | |
| 85651 | <1% | 1,225 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 69 | $1K |
| 71271 | <1% | 17 | $1K | |
| 85730 | <1% | 2,778 | $1K | |
| 82565 | <1% | 773 | $1K | |
| 81003 | <1% | 6,923 | $1K | |
| 82077 | <1% | 2,018 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 862 | $1K |
| 70486 | <1% | 14 | $1K | |
| 97167 | <1% | 16 | $1K | |
| 84702 | <1% | 1,011 | $1K | |
| 86850 | <1% | 679 | $993.62 | |
| 86900 | <1% | 1,303 | $950.56 | |
| 82803 | <1% | 697 | $822.28 | |
| 87205 | <1% | 698 | $674.39 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 757 | $664.14 |
| 86901 | <1% | 1,306 | $536.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,750 | $513.06 |
| 82728 | <1% | 46 | $417.06 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,679 | $389.84 |
| 72100 | <1% | 12 | $379.22 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 148 | $358.30 |
| 82607 | <1% | 54 | $357.25 | |
| 87147 | <1% | 598 | $319.08 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 28 | $316.95 |
| 86617 | <1% | 35 | $296.35 | |
| 73502 | <1% | 26 | $286.87 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,322 | $278.85 |
| 72050 | <1% | 14 | $277.70 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 44 | $272.96 |
| 83540 | <1% | 71 | $239.92 | |
| 80076 | <1% | 61 | $209.42 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,933 | $202.73 |
| 83520 | <1% | 25 | $184.71 | |
| 87210 | <1% | 603 | $171.13 | |
| 87899 | <1% | 82 | $169.51 | |
| 85018 | <1% | 56 | $165.07 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 22 | $152.95 |
| 83550 | <1% | 28 | $131.59 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,121 | $114.57 |
| 86618 | <1% | 41 | $104.71 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,180 | $99.93 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,360 | $99.18 |
| J1815 | Injection, insulin, per 5 units | <1% | 408 | $98.17 |
| 86038 | <1% | 14 | $86.02 | |
| 82962 | <1% | 252 | $85.64 | |
| 73090 | <1% | 12 | $74.33 | |
| 82570 | <1% | 30 | $66.19 | |
| C1769 | Guide wire | <1% | 73 | $53.61 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 745 | $52.39 |
| A9270 | Non-covered item or service | <1% | 3,626 | $51.00 |
| 82784 | <1% | 13 | $50.54 | |
| 86308 | <1% | 88 | $45.68 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 625 | $38.14 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 463 | $33.17 |
| 73080 | <1% | 13 | $28.84 | |
| 82274 | <1% | 44 | $27.31 | |
| 82248 | <1% | 18 | $20.40 | |
| 83498 | <1% | 12 | $13.84 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 237 | $12.49 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 218 | $10.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 14 | $7.17 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 127 | $5.47 |
| 82330 | <1% | 226 | $4.91 | |
| J3490 | Unclassified drugs | <1% | 1,882 | $4.50 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 95 | $3.96 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 255 | $3.42 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 226 | $3.41 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 20 | $2.30 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 40 | $2.00 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 15 | $1.38 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 12 | $0.69 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 59 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 56 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 101 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 49 | $0.00 |
| S4991 | Nicotine patches, non-legend | 0% | 19 | $0.00 |
| 73140 | 0% | 12 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 43 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 21 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 39 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 59 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 109 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,681 | $0.00 |
| 82150 | 0% | 13 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 273 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 78 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 27 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 14 | $0.00 |
| 87807 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTANTON, RACHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Pulaski Community Hospital INC | Pulaski, VA | $14.29M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.